Business
Manzo Pharmaceuticals Announces Positive Results From Laboratory Study of Lacto-Freedom Probiotic
Manzo Pharmaceuticals Announces Positive Results From Laboratory Study of Lacto-Freedom Probiotic.
About this update from Manzo Pharmaceuticals, Inc.
[{"type":"text","content":"\n\n\n\nManzo Pharmaceuticals Announces Positive Results From Laboratory Study of Lacto-Freedom Probiotic\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nManzo Pharmaceuticals Announces Positive Results From Laboratory Study of Lacto-Freedom Probiotic\nPR Newswire\nMILFORD, Pa., Feb. 3, 2015\n\n\n\nMILFORD, Pa., Feb. 3, 2015 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced positive results from the six month animal study of Lacto-Freedom™, the company's lactase producing probiotic. This successful testing brings Manzo Pharmaceuticals, and partner, Celprogen, Inc., one step closer to human clinical trials.    \n\nThe 6-month study was conducted by Celprogen,Inc. using laboratory rats to test the new probiotic treatment. Lab rats are the ideal mammals to test because they are naturally lactose intolerant.  After 6 months the rats given the treatment showed no negative side effects, even at very high doses.  All doses from low to high concentration were very successful at colonizing the intestines and producing lactase, which enabled rats to digest lactose.  In addition, the blood glucose levels of the rats was significantly higher after treatment, and for the full 6 months, demonstrating that the lactose in their diet was properly broken down into glucose and galactose.  This effect lasted for a full six months after the administration of the probiotic was discontinued.  This long lasting residual effect is unique and is far superior to any other lactose intolerance treatment option currently on the market.  Since approximately 25% of the population in the United States is lactose intolerant Manzo Pharmaceuticals and Celprogen are both confident that there will be a huge demand for this product.\n\nManzo Pharmaceuticals, Inc. also welcomes Dean Franchino to the project. Mr. Franchino has experience in the production of nutritional and pharmaceutical grade products, quality control, FDA regulations, research and development of new products and extensive knowledge of medical equipment. &...